Methylnaltrexone (Relistor) is a peripherally-acting μ-opioid antagonist used for the treatment of opioid induced constipation. Two independent organizations have recently published updated clinical information on this drug: Australian Prescriber. New drugs: Methylnaltrexone Health Canada. Summary Basis of Decision (SBD) RELISTOR The Scottish Medicines Consortium also reviewed Relistor in January 2009.
The Scottish Medicines Consortium issued on 8th December, 2008 an advice on the recently approved opioid antagonist methylnaltrexone ADVICE: following a full submissionMethylnaltrexone (Relistor) is accepted for restricted use within NHS Scotland for treatment of opioid-induced constipation in advanced illness patients who are receiving palliative care when response to usual laxative therapy has not been […]